Natural Alternatives International Inc. is a leading formulator, manufacturer, and marketer operating in the highly regulated nutritional supplements industry. The company’s primary business activity involves providing private-label contract manufacturing services to other companies that market and distribute health care and nutritional products. NAI offers a comprehensive suite of services, including scientific research, proprietary ingredient development, product testing, regulatory review, and international product registration assistance. The company leverages its expertise to assist clients in bringing a wide range of vitamins, minerals, and herbal supplements to both domestic and international markets.

The company generates revenue from two primary sources. The largest portion of sales comes from private-label contract manufacturing, where NAI handles the formulation and production of products for third-party companies. Additionally, NAI generates revenue through the licensing of its intellectual property and the direct sale of raw materials. These royalties and raw material sales are primarily associated with beta-alanine, which is commercialized through the direct sale of its raw material and associated supply agreements.

The company operates through the following reportable segments:

• Private-label contract manufacturing: This segment provides services to companies that require manufacturing and distribution of vitamins, minerals, and other nutritional supplements.

• Royalty, licensing, and raw material sales: This segment involves the commercialization of NAI’s patent and trademark estate related to beta-alanine. These activities support the direct distribution and sale of raw materials, as well as various license and royalty agreements. The core products and brands in this segment include CarnoSyn®, SR CarnoSyn®, and TriBsyn™.

NAI maintains a robust competitive position supported by superior quality assurance and regulatory compliance. The company holds certifications from major global bodies, including the Therapeutic Goods Administration (TGA) of Australia, NSF International (NSF), and Health Canada, which validate its commitment to Good Manufacturing Practices (GMP). These certifications enable product export into numerous countries, including most European and Pacific Rim nations. Furthermore, NAI's proprietary patent estate surrounding beta-alanine and its resulting formulations provide a significant, durable competitive advantage. The facility also holds multiple compliance certifications, such as Organic Processor and Handler status, Kosher, and Halal certifications, broadening its market accessibility and reputation for quality.

The company serves a diverse customer base consisting of businesses operating in various sales channels, including direct sales marketing networks, direct-to-consumer e-commerce platforms, and physical retail stores. Its private-label contract manufacturing customers are large organizations that market nutritional supplements internationally. The company's operational scope includes private-label contract manufacturing services sold both within the U. S. and in major international markets such as Europe, Asia, Mexico, and Canada. While the filing notes that the loss of any of its three largest private-label contract manufacturing customers could significantly impact its financial position, the company remains focused on expanding its client base to reduce this reliance.